Lipids as targets for novel anti-inflammatory therapies

Pharmacology and Therapeutics

Volumn 124, Issue 1, 2009, Pages 96-112

  Huwiler, Andrea ^a   Pfeilschifter, Josef ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anti inflammatory therapy; Cannabinoids; Ceramide; EETs; Eicosanoids; Lipids; PPARs; PUFAs; Sphingolipids; Sphingosine 1 phosphate

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ACETYLSALICYLIC ACID; AJULEMIC ACID; ANTIINFLAMMATORY AGENT; CANNABINOID RECEPTOR AGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; EPOXYICOSATRIENOIC ACID; FIBRIC ACID DERIVATIVE; FINGOLIMOD; GLITAZONE DERIVATIVE; INDOMETACIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LICOFELONE; LIPID; LIPOXIN; MONTELUKAST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOLIPASE A2 INHIBITOR; RIMONABANT; ROFECOXIB; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CLINICAL TRIAL; COLITIS; COLON CANCER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; EDEMA; GLOMERULONEPHRITIS; HUMAN; HYPERALGESIA; HYPERTRIGLYCERIDEMIA; IC 50; INFLAMMATORY DISEASE; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY ISCHEMIA; LIVER ISCHEMIA; LUNG INJURY; MULTIPLE SCLEROSIS; MYOCARDITIS; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOARTHRITIS; PAIN; PARKINSON DISEASE; PAW EDEMA; PERIODONTITIS; PERITONITIS; PLEURISY; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SKIN ALLERGY; SKIN INFLAMMATION; VIRUS MYOCARDITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CANNABINOIDS; FATTY ACIDS, UNSATURATED; HUMANS; LEUKOTRIENE ANTAGONISTS; LIPIDS; LIPOXINS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHOLIPASES A2; PHOSPHORYLCHOLINE; RECEPTORS, PROSTAGLANDIN E; SPHINGOLIPIDS; SPHINGOSINE;

EID: 68949157279     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.06.008     Document Type: Review

References (268)

1. Ackermann E.J., Conde-Frieboes K., and Dennis E.A. Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem 270 (1995) 445-450
2. Ahn K., Johnson D.S., Fitzgerald L.R., Liimatta M., Arendse A., Stevenson T., et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46 (2007) 13019-13030
3. Anselmo D., Amersi F.F., Shen X.D., Gao F., Katori M., Ke B., et al. FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury. Transplant Proc 34 (2002) 1467-1468
4. Arita M., Bianchini F., Aliberti J., Sher A., Chiang N., Hong S., et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201 (2005) 713-722
5. Arita M., Ohira T., Sun Y.P., Elangovan S., Chiang N., and Serhan C.N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178 (2007) 3912-3917
6. Ariel A., and Serhan C.N. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 28 (2007) 176-183
7. Bagga D., Wang L., Farias-Eisner R., Glaspy J.A., and Reddy S.T. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 100 (2003) 1751-1756
8. Ballou L.R., Chao C.P., Holness M.A., Barker S.C., and Raghow R. Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 267 (1992) 20044-20050
9. Balsinde J., Balboa M.A., and Dennis E.A. Inflammatory activation of arachidonic acid signaling in murine P388D1 macrophages via sphingomyelin synthesis. J Biol Chem 272 (1997) 20373-20377
10. Bannenberg G., Moussignac R.L., Gronert K., Devchand P.R., Schmidt B.A., Guilford W.J., et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 143 (2004) 43-52
11. Barish G.D., Narkar V.A., and Evans R.M. PPAR δ: a dagger in the heart of the metabolic syndrome. J Clin Invest 116 (2006) 590-597
12. Barish G.D., Atkins A.R., Downes M., Olson P., Chong L.W., Nelson M., et al. PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci U S A 105 (2008) 4271-4276
13. Bátkai S., Osei-Hyiaman D., Pan H., El-Assal O., Rajesh M., Mukhopadhyay P., et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 21 (2007) 1788-1800
14. Baxter C.S., and Miller M.L. Mechanism of mouse skin tumor promotion by n-dodecane. Carcinogenesis 8 (1987) 1787-1790
15. Behm D.J., Ogbonna A., Wu C., Burns-Kurtis C.L., and Douglas S.A. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 328 (2009) 231-239
16. Berger W., De Chandt M.T., and Cairns C.B. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 61 (2007) 663-676
17. Berridge M.J. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J 220 (1984) 345-360
18. Bertolini A., Ottani A., and Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res 44 (2001) 437-450
19. Bischoff A., Meyer Zu Heringdorf D., Jakobs K.H., and Michel M.C. Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. Br J Pharmacol 132 (2001) 1925-1933
20. Bisogno T., Melck D., Bobrov M., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351 (2000) 817-824
21. Bley K.R., Bhattacharya A., Daniels D.V., Gever J., Jahangir A., O'Yang C., et al. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol 147 (2006) 335-345
22. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., and Casellas P. Anandamide induced PPARγ transcriptional activation and 3 T3-L1 preadipocyte differentiation. Eur J Pharmacol 517 (2005) 174-181
23. Boukli L., Touaibia M., Meddad-Belhabich N., Djimdé A., Park C.H., Kim J.J., et al. Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4, 5-dihydro-1, 2, 4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines. Bioorg Med Chem 16 (2008) 1242-1253
24. Brady H.R., and Serhan C.N. Adhesion promotes transcellular leukotriene biosynthesis during neutrophil-glomerular endothelial cell interactions: inhibition by antibodies against CD18 and L-selectin. Biochem Biophys Res Commun 186 (1992) 1307-1314
25. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277 (2002) 21453-21457
26. Brodie M.J., Hensby C.N., Parke A., and Gordon D. Is prostacyclin the major pro-inflammatory prostanoid in joint fluid?. Life Sci 27 (1980) 603-608
27. Burke J.R., Davern L.B., Stanley P.L., Gregor K.R., Banville J., Remillard R., et al. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. J Pharmacol Exp Ther 298 (2001) 376-385
28. Bürli R.W., Xu H., Zou X., Muller K., Golden J., Frohn M., et al. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett 16 (2006) 3713-3718
29. Burstein S. PPAR-γ: a nuclear receptor with affinity for cannabinoids. Life Sci 77 (2005) 1674-1684
30. Burstein S.H., Karst M., Schneider U., and Zurier R.B. Ajulemic acid: a novel cannabinoid produces analgesia without a "high". Life Sci 75 (2004) 1513-1522
31. Calder P.C. Polyunsaturated fatty acids and inflammation. Biochem Soc Trans 33 (2005) 423-427
32. Calder P.C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52 (2008) 885-897
33. Calon F., and Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 77 (2007) 287-293
34. Chen J.K., Chen J., Imig J.D., Wei S., Hachey D.L., Guthi J.S., et al. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem 283 (2008) 24514-24524
35. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160 (1998) 5037-5044
36. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
37. Churi S.B., Abdel-Aleem O.S., Tumber K.K., Scuderi-Porter H., and Taylor B.K. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-γ to rapidly inhibit neuropathic pain in rats. J Pain 9 (2008) 639-649
38. Claria J., and Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92 (1995) 9475-9749
39. Clark P., Rowland S.E., Denis D., Mathieu M.C., Stocco R., Poirier H., et al. MF498 [N-{[4-(5, 9-Diethoxy-6-oxo-6, 8-dihydro-7H-pyrrolo[3, 4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther 325 (2008) 425-434
40. Clish C.B., O'Brien J.A., Gronert K., Stahl G.L., Petasis N.A., and Serhan C.N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A 96 (1999) 8247-8252
41. Coffey R.G., Snella E., Johnson K., and Pross S. Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro. Int J Immunopharmacol 18 (1996) 749-752
42. Costa Rosa L.F., Safi D.A., and Guimarães A.R. The effect of n- 3 PUFA rich diet upon macrophage and lymphocyte metabolism and function. Biochem Mol Biol Int 40 (1996) 833-842
43. Costet P., Legendre C., Moré J., Edgar A., Galtier P., and Pineau T. Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273 (1998) 29577-29585
44. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98 (2001) 9371-9376
45. Cummings B.S. Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 74 (2007) 949-959
46. Cuzzocrea S., Wayman N.S., Mazzon E., Dugo L., Di Paola R., Serraino I., et al. The cyclopentenone prostaglandin 15-deoxy-Delta(12, 14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol 61 (2002) 997-1007
47. Cuzzocrea S., Mazzon E., Dugo L., Patel N.S., Serraino I., Di Paola R., et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor γ. Arthritis Rheum 48 (2003) 3544-3556
48. Dabu-Bondoc S., and Franco S. Risk-benefit perspectives in COX-2 blockade. Curr Drug Saf 3 (2008) 14-23
49. Davis B.B., Thompson D.A., Howard L.L., Morisseau C., Hammock B.D., and Weiss R.H. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 99 (2002) 2222-2227
50. Delayre-Orthez C., Becker J., Auwerx J., Frossard N., and Pons F. Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate. Eur J Pharmacol 581 (2008) 177-184
51. Delerive P., De Bosscher K., Besnard S., van den Berghe W., Peters J.M., Gonzalez F.J., et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274 (1999) 32048-32054
52. Deplanque D., Gelé P., Pétrault O., Six I., Furman C., Bouly M., et al. Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23 (2003) 6264-6271
53. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
54. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
55. Dol-Gleizes F., Paumelle R., Visentin V., Marés A.M., Desitter P., Hennuyer N., et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 29 (2009) 12-18
56. Dorrance A.M., Rupp N., Pollock D.M., Newman J.W., Hammock B.D., and Imig J.D. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46 (2005) 842-848
57. Edwards I.J., and O'Flaherty J.T. Omega-3 fatty acids and PPARγ in cancer. PPAR Res 2008 (2008) 358052
58. Feizi A., Jafari M.R., Hamedivafa F., Tabrizian P., and Djahanguiri B. The preventive effect of cannabinoids on reperfusion-induced ischemia of mouse kidney. Exp Toxicol Pathol 60 (2008) 405-410
59. Fierro I.M., Colgan S.P., Bernasconi G., Petasis N.A., Clish C.B., Arita M., et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J Immunol 170 (2003) 2688-2694
60. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 82 (2007) 60-67
61. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci U S A 94 (1997) 4312-4317
62. Friesen R.W., and Mancini J.A. Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. J Med Chem 51 (2008) 4059-4067
63. Frohn M., Xu H., Zou X., Chang C., McElvaine M., Plant M.H., et al. New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation. Bioorg Med Chem Lett 17 (2007) 6633-6637
64. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodríguez De Fonseca F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425 (2003) 90-93
65. Fujino M., Funeshima N., Kitazawa Y., Kimura H., Amemiya H., Suzuki S., et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305 (2003) 70-77
66. Fujishiro J., Kudou S., Iwai S., Takahashi M., Hakamata Y., Kinoshita M., et al. Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation 82 (2006) 804-812
67. García-Arencibia M., González S., de Lago E., Ramos J.A., Mechoulam R., and Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134 (2007) 162-170
68. Genovese T., Mazzon E., Di Paola R., Muià C., Crisafulli C., Caputi A.P., et al. role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor α in the development of bleomycin-induced lung injury. Shock 24 (2005) 547-555
69. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Staels B., et al. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate. J Biol Chem 279 (2004) 16154-16160
70. Gewirtz A.T., Collier-Hyams L.S., Young A.N., Kucharzik T., Guilford W.J., Parkinson J.F., et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 168 (2002) 5260-5267
71. Godson C., Mitchell S., Harvey K., Petasis N.A., Hogg N., and Brady H.R. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164 (2000) 1663-1667
72. Graf C., Klumpp M., Habig M., Rovina P., Billich A., Baumruker T., et al. Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol Pharmacol 74 (2008) 925-932
73. Graf C., Zemann B., Rovina P., Urtz N., Schanzer A., Reuschel R., Mechtcheriakova D., et al. Neutropenia with impaired immune response to Streptococcus pneumoniae in ceramide kinase-deficient mice. J Immunol 180 (2008) 3457-3466
74. Gronert K. Lipoxins in the eye and their role in wound healing. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 221-229
75. Gronert K., Gewirtz A., Madara J.L., and Serhan C.N. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon γ and inhibits tumor necrosis factor α-induced IL-8 release. J Exp Med 187 (1998) 128512-128594
76. Gross G.J., Gauthier K.M., Moore J., Falck J.R., Hammock B.D., Campbell W.B., et al. Effects of the selective EET antagonist, 14, 15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 294 (2008) H2838-H2844
77. Guilford W.J., and Parkinson J.F. Second-generation β-oxidation resistant 3-oxa-lipoxin A4 analogs. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 245-250
78. Hachicha M., Pouliot M., Petasis N.A., and Serhan C.N. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 189 (1999) 1923-1930
79. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 96 (1999) 14228-14233
80. Hara J., Higuchi K., Okamoto R., Kawashima M., and Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 115 (2000) 406-413
81. Haraguchi K., Shimura H., and Onaya T. Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor PPARγ activators. Clin Exp Nephrol 7 (2003) 27-32
82. Hashimoto K., Ethridge R.T., Saito H., Rajaraman S., and Evers B.M. The PPARγ ligand, 15d-PGJ2, attenuates the severity of cerulein-induced acute pancreatitis. Pancreas 27 (2003) 58-66
83. Haskova Z., Hoang B., Luo G., Morgan L.A., Billin A.N., Barone F.C., et al. Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARβ/δ ligand GW0742. Inflamm Res 57 (2008) 314-321
84. Hecht, I., Jiang, R., Sampaio, A.L., Hermesh, C., Rutledge, C., Shemesh, R., et al. (2008). A novel peptide agonist of FPRL1 (ALX) displays anti-inflammatory and cardioprotective effects. J Pharmacol Exp Ther 328, 426-434.
85. Higuchi K., Hara J., Okamoto R., Kawashima M., and Imokawa G. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 350 (2000) 747-756
86. Hollingshead H.E., Borland M.G., Billin A.N., Willson T.M., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29 (2008) 169-176
87. Holt S., Comelli F., Costa B., and Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146 (2005) 467-476
88. Hong S., Porter T.F., Lu Y., Oh S.F., Pillai P.S., and Serhan C.N. Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol 180 (2008) 3512-3519
89. Hu S., and Kim H.S. Activation of K + channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur J Pharmacol 230 (1993) 215-221
90. Huffman J.W., Zengin G., Wu M.J., Lu J., Hynd G., Bushell K., et al. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem 13 (2005) 89-112
91. Huffman J.W., Bushell S.M., Joshi S.N., Wiley J.L., and Martin B.R. Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg Med Chem 14 (2006) 247-262
92. Hughes J.E., Srinivasan S., Lynch K.R., Proia R.L., Ferdek P., and Hedrick C.C. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 102 (2008) 950-958
93. Huwiler A., Johansen B., Skarstad A., and Pfeilschifter J. Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J 15 (2001) 7-9
94. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100 (2003) 10529-10533
95. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46 (2005) 975-981
96. Inceoglu B., Schmelzer K.R., Morisseau C., Jinks S.L., and Hammock B.D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82 (2007) 42-49
97. Inceoglu B., Jinks S.L., Ulu A., Hegedus C.M., Georgi K., Schmelzer K.R., et al. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A 105 (2008) 18901-18906
98. Iwashita A., Muramatsu Y., Yamazaki T., Muramoto M., Kita Y., Yamazaki S., et al. Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo. J Pharmacol Exp Ther 320 (2007) 1087-1096
99. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147 (2006) 281-288
100. Jeon Y.J., Yang K.H., Pulaski J.T., and Kaminski N.E. Attenuation of inducible nitric oxide synthase gene expression by Δ9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol 50 (1996) 334-341
101. Jiang C., Ting A.T., and Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
102. Jung O., Brandes R.P., Kim I.H., Schweda F., Schmidt R., Hammock B.D., et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45 (2005) 759-765
103. Kalyvas A., and David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 41 (2004) 323-335
104. Karp C.L., Flick L.M., Yang R., Uddin J., and Petasis N.A. Cystic fibrosis and lipoxins. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 263-270
105. Keul P., Tölle M., Lucke S., von Wnuck Lipinski K., Heusch G., Schuchardt M., et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 607-613
106. Kilgore K.S., and Billin A.N. PPARβ/δ ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 9 (2008) 463-469
107. Klapisz E., Masliah J., Béréziat G., Wolf C., and Koumanov K.S. Sphingolipids and cholesterol modulate membrane susceptibility to cytosolic phospholipase A(2). J Lipid Res 41 (2000) 1680-1688
108. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5 (2005) 400-411
109. Koeberle A., Siemoneit U., Bühring U., Northoff H., Laufer S., Albrecht W., et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 326 (2008) 975-982
110. Kohno H., Suzuki R., Sugie S., and Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5 (2005) 46
111. Kölzer M., Werth N., and Sandhoff K. Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett 559 (2004) 96-98
112. Krämer H.J., Stevens J., Grimminger F., and Seeger W. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol 52 (1996) 1211-1217
113. LaBuda C.J., Koblish M., and Little P.J. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527 (2005) 172-174
114. Lambeau G., and Gelb M.H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 77 (2008) 495-520
115. Lee J.W., Bajwa P.J., Carson M.J., Jeske D.R., Cong Y., Elson C.O., et al. Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 133 (2007) 108-123
116. Leonard M.O., Hannan K., Burne M.J., Lappin D.W., Doran P., Coleman P., et al. 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 13 (2002) 1657-1662
117. Leslie C.A., Gonnerman W.A., Ullman M.D., Hayes K.C., Franzblau C., and Cathcart E.S. Dietary fish oil modulates macrophage fatty acids and decreases arthritis susceptibility in mice. J Exp Med 162 (1985) 1336-1349
118. Levy B.D. Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 231-237
119. Levy B.D., Clish C.B., Schmidt B., Gronert K., and Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2 (2001) 612-619
120. Li Y., Kang J.X., and Leaf A. Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiac myocytes. Prostaglandins 54 (1997) 511-530
121. Li P.L., Zou A.P., and Campbell W.B. Regulation of potassium channels in coronary arterial smooth muscle by endothelium-derived vasodilators. Hypertension 29 (1997) 262-267
122. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
123. Lien Y.H., Yong K.C., Cho C., Igarashi S., and Lai L.W. S1P1-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int 69 (2006) 1601-1608
124. Liliom K., Sun G., Bünemann M., Virág T., Nusser N., Baker D.L., et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 355 (2001) 189-197
125. Lin C.R., Amaya F., Barrett L., Wang H., Takada J., Samad T.A., et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319 (2006) 1096-1103
126. Liu G., Bibus D.M., Bode A.M., Ma W.Y., Holman R.T., and Dong Z. Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells. Proc Natl Acad Sci USA 98 (2001) 7510-7515
127. Liu J., Batkai S., Pacher P., Harvey-White J., Wagner J.A., Cravatt B.F., et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-κB independently of platelet-activating factor. J Biol Chem 278 (2003) 45034-45039
128. Liu Y., Zhang Y., Schmelzer K., Lee T.S., Fang X., Zhu Y., et al. The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102 (2005) 16747-16752
129. Lo C.J., Chiu K.C., Fu M., Lo R., and Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NFκB activity. J Surg Res 82 (1999) 216-221
130. LoVerme J., Russo R., La Rana G., Fu J., Farthing J., Mattace-Raso G., et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-α. J Pharmacol Exp Ther 319 (2006) 1051-1061
131. Lucas K.K., Svensson C.I., Hua X.Y., Yaksh T.L., and Dennis E.A. Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. Br J Pharmacol 144 (2005) 940-952
132. Ma L.J., Marcantoni C., Linton M.F., Fazio S., and Fogo A.B. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59 (2001) 1899-1910
133. Maddox J.F., Hachicha M., Takano T., Petasis N.A., Fokin V.V., and Serhan C.N. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem 272 (1997) 6972-6978
134. Maki T., Gottschalk R., and Monaco A.P. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 74 (2002) 1684-1686
135. Malan Jr. T.P., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 (2001) 239-245
136. Malaviya R., Ansell J., Hall L., Fahmy M., Argentieri R.L., Olini Jr. G.C., et al. Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice. Eur J Pharmacol 539 (2006) 195-204
137. Marriott K.S., Huffman J.W., Wiley J.L., and Martin B.R. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor. Bioorg Med Chem 14 (2006) 2386-2397
138. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
139. Marx N., Kehrle B., Kohlhammer K., Grüb M., Koenig W., Hombach V., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90 (2002) 703-710
140. Massa F., Marsicano G., Hermann H., Cannich A., Monory K., Cravatt B.F., et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113 (2004) 1202-1209
141. Matsuura M., Imayoshi T., and Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol 22 (2000) 323-331
142. McGuinness J., Byrne J., Condron C., McCarthy J., Bouchier-Hayes D., and Redmond J.M. Pretreatment with omega-3 fatty acid infusion to prevent leukocyte-endothelial injury responses seen in cardiac surgery. J Thorac Cardiovasc Surg 136 (2008) 135-141
143. McKenney J.M., and Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27 (2007) 715-728
144. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
145. Mechoulam R., Peters M., Murillo-Rodriguez E., and Hanus L.O. Cannabidiol-recent advances. Chem Biodivers 4 (2007) 1678-1692
146. Meyer M.C., Rastogi P., Beckett C.S., and McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 11 (2005) 1301-1312
147. Meyer Zu Heringdorf D., Himmel H.M., and Jakobs K.H. Sphingosylphosphorylcholine-biological functions and mechanisms of action. Biochim Biophys Acta 1582 (2002) 178-189
148. Milman G., Maor Y., Abu-Lafi S., Horowitz M., Gallily R., Batkai S., et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 103 (2006) 2428-2433
149. Mitchell S., Thomas G., Harvey K., Cottell D., Reville K., Berlasconi G., et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 13 (2002) 2497-2507
150. Miyamoto T., Matsumori A., Hwang M.W., Nishio R., Ito H., and Sasayama S. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol 37 (2001) 1713-1718
151. Mizushima T., Ito T., Kishi D., Kai Y., Tamagawa H., Nezu R., et al. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 10 (2004) 182-192
152. Molina-Holgado F., Lledó A., and Guaza C. Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8 (1997) 1929-1933
153. Mor M., Rivara S., Lodola A., Plazzi P.V., Tarzia G., Duranti A., et al. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 47 (2004) 4998-5008
154. Moreno J.J. New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochem Pharmacol 77 (2009) 1-10
155. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A 96 (1999) 8849-8854
156. Motoki A., Merkel M.J., Packwood W.H., Cao Z., Liu L., Iliff J., et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 295 (2008) H2128-H2134
157. Mukherjee P.K., Marcheselli V.L., Serhan C.N., and Bazan N.G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 101 (2004) 8491-8496
158. Murakami M., and Kudo I. Secretory phospholipase A2. Biol Pharm Bull 27 (2004) 1158-1164
159. Murata Y., Ogata J., Higaki Y., Kawashima M., Yada Y., Higuchi K., et al. Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency?. J Invest Dermatol 106 (1996) 1242-1249
160. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 (1997) 678-682
161. Murch O., Abdelrahman M., Collino M., Gallicchio M., Benetti E., Mazzon E., et al. Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. Crit Care Med 36 (2008) 550-559
162. Nackley A.G., Makriyannis A., and Hohmann A.G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119 (2003) 747-757
163. Nagase T., Uozumi N., Aoki-Nagase T., Terwaki K., Ishii S., Tomita T., et al. A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 284 (2003) L720-726
164. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 118 (2008) 18-35
165. Nakajima A., Wada K., Miki H., Kubota N., Nakajima N., Terauchi Y., et al. Endogenous PPAR γ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120 (2001) 460-469
166. Nakao K., Murase A., Ohshiro H., Okumura T., Taniguchi K., Murata Y., et al. CJ-023, 423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322 (2007) 686-694
167. Natarajan C., Muthian G., Barak Y., Evans R.M., and Bright J.J. Peroxisome proliferator-activated receptor-γ-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol 171 (2003) 5743-5750
168. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 5 (2004) 679-686
169. Nevalainen T.J., Hietaranta A.J., and Gronroos J.M. Phospholipase A2 in acute pancreatitis: new biochemical and pathological aspects. Hepatogastroenterology 46 (1999) 2731-2735
170. Ng V.Y., Huang Y., Reddy L.M., Falck J.R., Lin E.T., and Kroetz D.L. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 35 (2007) 1126-1134
171. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9 (1995) 484-496
172. Nixon G.F., Mathieson F.A., and Hunter I. The multi-functional role of sphingosylphosphorylcholine. Prog Lipid Res 47 (2008) 62-75
173. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
174. Node K., Ruan X.L., Dai J., Yang S.X., Graham L., Zeldin D.C., et al. Activation of Gαs mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276 (2001) 15983-15989
175. Nofer J.R., and Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 15 (2005) 265-271
176. Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113 (2004) 569-581
177. O'Connor P., Comi G., Montalban X., Antel J., Radue E.W., de Vera A., et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72 (2009) 73-79
178. Ogawa R., Takahashi M., Hirose S., Morimoto H., Ise H., Murakami T., et al. A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. Biochem Biophys Res Commun 361 (2007) 621-628
179. Oka S., Wakui J., Ikeda S., Yanagimoto S., Kishimoto S., Gokoh M., et al. Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol 177 (2006) 8796-8805
180. Okumura T., Murata Y., Taniguchi K., Murase A., and Nii A. Effects of the selective EP4 antagonist, CJ-023, 423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis. J Pharm Pharmacol 60 (2008) 723-730
181. O'Meara Y.M., and Brady H.R. Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis. Kidney Int Suppl 58 (1997) S56-S61
182. Park C.W., Zhang Y., Zhang X., Wu J., Chen L., Cha D.R., et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69 (2006) 1511-1517
183. Parrish A.R., Chen G., Burghardt R.C., Watanabe T., Morisseau C., and Hammock B.D. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol (2008) Electronic publication Apr 3
184. Paul-Clark M.J., Van Cao T., Moradi-Bidhendi N., Cooper D., and Gilroy D.W. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 200 (2004) 69-78
185. Peng X., Hassoun P.M., Sammani S., McVerry B.J., Burne M.J., Rabb H., et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 169 (2004) 1245-1251
186. Perretti M., Chiang N., La M., Fierro I.M., Marullo S., Getting S.J., et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 8 (2002) 1296-1302
187. Petasis N.A., Keleddjian R., Sun Y.P., Nagulapalli K.C., Tjonahen E., Yang R., et al. Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg Med Chem Lett 18 (2008) 1382-1387
188. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor a-deficient mice. J Biol Chem 272 (1997) 27307-27312
189. Peters H., Martini S., Wang Y., Shimizu F., Kawachi H., Krämer S., et al. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int 66 (2004) 1434-1443
190. Pettus B.J., Bielawska A., Spiegel S., Roddy P., Hannun Y.A., and Chalfant C.E. Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. J Biol Chem 278 (2003) 38206-38213
191. Pettus B.J., Bielawski J., Porcelli A.M., Reames D.L., Johnson K.R., Morrow J., et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. FASEB J 17 (2003) 1411-1421
192. Pettus B.J., Bielawska A., Subramanian P., Wijesinghe D.S., Maceyka M., Leslie C.C., et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem 279 (2004) 11320-11326
193. Phillips E.D., Chang H.F., Holmquist C.R., and McCauley J.P. Synthesis of methyl (5 S, 6R, 7E, 9E, 11Z, 13E, 15 S)-16-(4-fluorophenoxy)-5, 6, 15-trihydroxy-7, 9, 11, 13-hexadecatetraenoate, an analogue of 15R-lipoxin A4. Bioorg Med Chem Lett 13 (2003) 3223-3226
194. Polak P.E., Kalinin S., Dello Russo C., Gavrilyuk V., Sharp A., Peters J.M., et al. Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 168 (2005) 65-75
195. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 301 (2002) 1020-1024
196. Pouliot M., Clish C.B., Petasis N.A., Van Dyke T.E., and Serhan C.N. Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39 (2000) 4761-4768
197. Price P.T., Nelson C.M., and Clarke S.D. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol 11 (2000) 3-7
198. Pulichino A.M., Rowland S., Wu T., Clark P., Xu D., Mathieu M.C., et al. Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther 319 (2006) 1043-1050
199. Radeke H.H., von Wenckstern H., Stoidtner K., Sauer B., Hammer S., and Kleuser B. Overlapping signaling pathways of sphingosine 1-phosphate and TGF-β in the murine Langerhans cell line XS52. J Immunol 174 (2005) 2778-2786
200. Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell Biochem 42 (2007) 3-27
201. Rajesh M., Pan H., Mukhopadhyay P., Bátkai S., Osei-Hyiaman D., Haskó G., et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 82 (2007) 1382-1389
202. Rausch M., Hiestand P., Foster C.A., Baumann D.R., Cannet C., and Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 20 (2004) 16-24
203. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
204. Risse D., Elfringhoff A.S., and Lehr M. Determination of the cell lytic properties of amphiphilic inhibitors of the cytosolic phospholipase A2 against human platelets by measuring the liberation of serotonin with high-performance liquid chromatography and fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 769 (2002) 185-190
205. Romano M., Chen X.S., Takahashi Y., Yamamoto S., Funk C.D., and Serhan C.N. Lipoxin synthase activity of human platelet 12-lipoxygenase. Biochem J 296 (1993) 127-133
206. Sahagun-Ruiz A., Colla J.S., Juhn J., Gao J.L., Murphy P.M., and McDermott D.H. Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun 2 (2001) 335-342
207. Sanderson P., MacPherson G.G., Jenkins C.H., and Calder P.C. Dietary fish oil diminishes the antigen presentation activity of rat dendritic cells. J Leukoc Biol 62 (1997) 771-777
208. Saubermann L.J., Nakajima A., Wada K., Zhao S., Terauchi Y., Kadowaki T., et al. Peroxisome proliferator-activated receptor γ agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 8 (2002) 330-339
209. Sauer B., Vogler R., von Wenckstern H., Fujii M., Anzano M.B., Glick A.B., et al. Involvement of Smad signaling in sphingosine 1-phosphate-mediated biological responses of keratinocytes. J Biol Chem 279 (2004) 38471-38479
210. Sawicka E., Zuany-Amorim C., Manlius C., Trifilieff A., Brinkmann V., Kemeny D.M., et al. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol 171 (2003) 6206-6214
211. Schaloske R.H., and Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761 (2006) 1246-1259
212. Schevitz R.W., Bach N.J., Carlson D.G., Chirgadze N.Y., Clawson D.K., Dillard R.D., et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol 2 (1995) 458-465
213. Schmidt A., Geigenmüller S., Völker W., and Buddecke E. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt --> NF-κB signalling pathways in human vascular endothelial cells. Basic Res Cardiol 101 (2006) 109-116
214. Schmuth M., Haqq C.M., Cairns W.J., Holder J.C., Dorsam S., Chang S., et al. Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 122 (2004) 971-983
215. Schottelius A.J., Giesen C., Asadullah K., Fierro I.M., Colgan S.P., Bauman J., et al. An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol 169 (2002) 7063-7070
216. Schwab J.M., and Serhan C.N. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 6 (2006) 414-420
217. Schwab J.M., Chiang N., Arita M., and Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 (2007) 869-874
218. Serhan C.N., and Sheppard K.A. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 85 (1990) 772-780
219. Serhan C.N., Hamberg M., and Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 81 (1984) 5335-5339
220. Serhan C.N., Gotlinger K., Hong S., and Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat 73 (2004) 155-172
221. Shan W., Palkar P.S., Murray I.A., McDevitt E.I., Kennett M.J., Kang B.H., et al. Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 105 (2008) 418-428
222. Skoura A., Sanchez T., Claffey K., Mandala S.M., Proia R.L., and Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest 117 (2007) 2506-2516
223. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., and Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 102 (2005) 2186-2191
224. Sohda T., Mizuno K., Tawada H., Sugiyama Y., Fujita T., and Kawamatsu Y. Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2, 4-dione (AL-321) and related compounds. Chem. Pharm Bull (Tokyo) 30 (1982) 3563-3573
225. Song J., Matsuda C., Kai Y., Nishida T., Nakajima K., Mizushima T., et al. A novel sphingosine 1-phosphate receptor agonist, KRP-203, regulates chronic colitis in IL-10 gene-deficient mice. J Pharmacol Exp Ther 324 (2008) 276-283
226. Spector A.A., and Norris A.W. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292 (2007) C996-C1012
227. Spiecker M., and Liao J.K. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433 (2005) 413-420
228. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARγ activators. Nature 393 (1998) 790-793
229. Staels B., Maes M., and Zambon A. Fibrates and future PPARα agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 5 (2008) 542-553
230. Stahelin R.V., Subramanian P., Vora M., Cho W., and Chalfant C.E. Ceramide-1-phosphate binds group IVA cytosolic phospholipase A2 via a novel site in the C2 domain. J Biol Chem 282 (2007) 20467-20474
231. Staumont-Sallé D., Abboud G., Brénuchon C., Kanda A., Roumier T., Lavogiez C., et al. Peroxisome proliferator-activated receptor α regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121 (2008) 962-968
232. Sumariwalla P.F., Gallily R., Tchilibon S., Fride E., Mechoulam R., and Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 50 (2004) 985-998
233. Sun Y., Alexander S.P., Kendall D.A., and Bennett A.J. Cannabinoids and PPARα signalling. Biochem Soc Trans 34 (2006) 1095-1097
234. Suzuki S., Enosawa S., Kakefuda T., Shinomiya T., Amari M., Naoe S., et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 61 (1996) 200-205
235. Svensson C.I., Lucas K.K., Hua X.Y., Powell H.C., Dennis E.A., and Yaksh T.L. Spinal phospholipase A2 in inflammatory hyperalgesia: role of the small, secretory phospholipase A2. Neuroscience 133 (2005) 543-553
236. Svensson C.I., Zattoni M., and Serhan C.N. Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J Exp Med 204 (2007) 245-252
237. Takano T., Fiore S., Maddox J.F., Brady H.R., Petasis N.A., and Serhan C.N. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med 185 (1997) 1693-1704
238. Tauzin L., Graf C., Sun M., Rovina P., Bouveyron N., Jaritz M., et al. Effects of ceramide-1-phosphate on cultured cells: dependence on dodecane in the vehicle. J Lipid Res 48 (2007) 66-76
239. Teichgräber V., Ulrich M., Endlich N., Riethmüller J., Wilker B., De Oliveira-Munding C.C., et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14 (2008) 382-391
240. Terano T., Salmon J.A., Higgs G.A., and Moncada S. Eicosapentaenoic acid as a modulator of inflammation. Effect on prostaglandin and leukotriene synthesis. Biochem Pharmacol 35 (1986) 779-785
241. Tham C.S., Whitaker J., Luo L., and Webb M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett 581 (2007) 2899-2904
242. Tölle M., Levkau B., Keul P., Brinkmann V., Giebing G., Schönfelder G., et al. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res 96 (2005) 913-920
243. Tölle M., Levkau B., Kleuser B., and van der Giet M. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. Eur J Clin Invest 37 (2007) 171-179
244. Troncoso P., Ortíz M., Martínez L., and Kahan B.D. FTY 720 prevents ischemic reperfusion damage in rat kidneys. Transplant Proc 33 (2001) 857-859
245. Vadas P., Browning J., Edelson J., and Ppruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 8 (1993) 1-30
246. van der Giet M., Tölle M., and Kleuser B. Relevance and potential of sphingosine-1-phosphate in vascular inflammatory disease. Biol Chem 389 (2008) 1381-1390
247. Vane J.R., and Botting R.M. Mechanism of action of antiinflammatory drugs. Int J Tissue React 20 (1998) 3-15
248. Vaughn M.W., Proske R.J., and Haviland D.L. Identification, cloning, and functional characterization of a murine lipoxin A4 receptor homologue gene. J Immunol 169 (2002) 3363-3369
249. Venkatraman M.S., Chittiboyina A., Meingassner J., Ho C.I., Varani J., Ellis C.N., et al. α-Lipoic acid-based PPARγ agonists for treating inflammatory skin diseases. Arch Dermatol Res 296 (2004) 97-104
250. 2+ permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 97 (2005) 908-915
251. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113 (2003) 159-170
252. Wang M., Song W.L., Cheng Y., and Fitzgerald G.A. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med 263 (2008) 500-505
253. Werz O., and Steinhilber D. Development of 5-lipoxygenase inhibitors- lessons from cellular enzyme regulation. Biochem Pharmacol 70 (2005) 327-333
254. Werz O., and Steinhilber D. Pharmacological intervention with 5-lipoxygenase; new insights and novel compounds. Expert Opin Ther Patents 15 (2005) 505-519
255. Whelan J., Broughton K.S., Lokesh B., and Kinsella J.E. In vivo formation of leukotriene E5 by murine peritoneal cells. Prostaglandins 41 (1991) 29-42
256. Whetzel A.M., Bolick D.T., Srinivasan S., Macdonald T.L., Morris M.A., Ley K., et al. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 99 (2006) 731-739
257. Wu S.H., Wu X.H., Liao P.Y., and Dong L. Signal transduction involved in protective effects of 15(R/S)-methyl- lipoxin A(4) on mesangioproliferative nephritis in rats. Prostaglandins Leukot Essent Fatty Acids 76 (2007) 173-180
258. Xin C., Ren S., Kleuser B., Shabahang S., Eberhardt W., Radeke H., et al. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-β-induced cell responses. J Biol Chem 279 (2004) 35255-35262
259. Xin C., Ren S., Eberhardt W., Pfeilschifter J., and Huwiler A. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 147 (2006) 164-174
260. Xin C., Ren S., Eberhardt W., Pfeilschifter J., and Huwiler A. FTY720 suppresses interleukin-1β-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism. Br J Pharmacol 150 (2007) 943-950
261. Xin C., Ren S., Eberhardt W., Pfeilschifter J., and Huwiler A. Sphingosylphosphorylcholine acts in an anti-inflammatory manner in renal mesangial cells by reducing interleukin-1β-induced prostaglandin E2 formation. J Lipid Res 48 (2007) 1985-1996
262. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3 (1999) 397-403
263. Xu X., Otsuki M., Saito H., Sumitani S., Yamamoto H., Asanuma N., et al. PPARα and GR differentially down-regulate the expression of nuclear factor-κB-responsive genes in vascular endothelial cells. Endocrinology 142 (2001) 3332-3339
264. Xu D., Rowland S.E., Clark P., Giroux A., Cote B., Guiral S., et al. MF63 [2-(6-chloro-1H-phenanthro[9, 10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 326 (2008) 754-763
265. Yang B., Graham L., Dikalov S., Mason R.P., Falck J.R., Liao J.K., et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 60 (2001) 310-320
266. Yang W., Tuniki V.R., Anjaiah S., Falck J.R., Hillard C.J., and Campbell W.B. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14, 15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324 (2008) 1019-1027
267. Zhao W., Iskandar S., Kooshki M., Sharpe J.G., Payne V., and Robbins M.E. Knocking out peroxisome proliferator-activated receptor (PPAR) α inhibits radiation-induced apoptosis in the mouse kidney through activation of NF-κB and increased expression of IAPs. Radiat Res 167 (2007) 581-591
268. Zurier R.B., Sun Y.P., George K.L., Stebulis J.A., Rossetti R.G., Skulas A., et al. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J (2009) Electronic publication Jan 5